Project Grant R21CA296671
Award Date
12/1/24
Completion Date
11/30/26
Dollars Obligated
$219K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Jacksonville, FL 32224, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $103,948 to Wayne State University to investigate the role of the Ran guanine exchange factor, RCC1, in pancreatic ductal adenocarcinoma (PDAC) progression. The objectives are to study how RCC1 impacts PDAC metabolic activity and mRNA processing, as well as examine the effects of RCC1 overexpression on PDAC development and metastasis using animal models. The award period runs...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Biology Research program (CFDA 93.396), provides $698,008 to The Trustees of the University of Pennsylvania to conduct research on the regulation of histone propionylation in pancreatic ductal adenocarcinoma (PDA). The project aims to elucidate the mechanism by which branched-chain amino acid metabolism generates nuclear propionyl-CoA to modulate histone propionylation and gene expression, with the goal...
This federal Project Grant award of $269,280 from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), supports research to determine the biological effects and antitumor activity of a senescent cell-targeted antibody, SIWA318, in preclinical models of pancreatic ductal adenocarcinoma (PDAC). The research aims to evaluate whether depletion of senescent and pro-fibrotic cells in the PDAC tumor microenvironment can improve the efficacy of standard-of-care...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $219,491 to the Mayo Clinic Jacksonville to conduct research on the epigenetic regulation of T cell metabolism and immune functions by the SIRT6 protein. The research aims to understand how SIRT6 impacts the metabolic activity and effector functions of tumor-reactive T cells, with the goal of identifying ways to boost T cell metabolism and enhance cancer immunotherapies. The study will...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $654,197 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research on pancreatic cancer patient-derived xenograft (PDX) tumor models. The research aims to: Define the molecular subtypes of pancreatic ductal adenocarcinoma (PDAC) that respond to standard-of-care chemotherapies like FOLFIRINOX and gemcitabine + Abraxane. Elucidate how...
This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $432,889 to The Johns Hopkins University to conduct research aimed at advancing cancer screening, diagnostic technologies, and early detection methodologies. The project, titled "Molecular Imaging and Metabolotheranostics of PDAC-Induced Cachexia", will focus on reversing cachexia (severe muscle wasting) induced by pancreatic ductal adenocarcinoma...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $145,000.00 in funding to the University of Oklahoma Health Sciences Center to investigate the role of the JMJD4 enzyme in pancreatic cancer. The research aims to determine how JMJD4 affects the growth and invasiveness of pancreatic tumor cells, as well as its potential mechanisms of action through modulating transcription factors NRF2 and HIF-2A. This work is expected to advance...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $192,240 to The University of Texas MD Anderson Cancer Center to conduct research on the functional contribution of extracellular vesicles in pancreatic cancer. The research aims to investigate how cancer cell-derived extracellular vesicles modulate the tumor microenvironment to facilitate pancreatic cancer initiation, progression, and metastasis. The goal is to identify novel...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) totaling $429,079 provides funding to Mayo Clinic to investigate the role of the protein VAV1 in regulating glutamine metabolism and its impact on tumor progression and metastasis in pancreatic cancer. The key objectives of this 5-year research program are to: 1) define how VAV1 promotes the conversion of glutamine to glutamate, and 2) elucidate how the resulting glutamate production...
This Project Grant award, titled "A NOVEL IMMUNOTHERAPY FOR PANCREATIC CANCER USING MICRO-RNA-29A," was provided by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) to the University of Miami in the amount of $107,948. The award will support research to determine the contribution of the TNFR2-miR-29a axis to CD8 T cell dysfunction in pancreatic ductal adenocarcinoma (PDAC), with the goal of generating durable T-cell mediated anti-tumor activity. The...